

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Buparvaquone Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Skin irritation : Category 2

Eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure : Category 3

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.

Buparvaquone Formulation

Version 4.1 Revision Date: 10.10.2020 SDS Number: 2091186-00007 Date of last issue: 23.03.2020
 Date of first issue: 17.10.2017

H360D May damage the unborn child.
 H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements

:

Prevention:

P201 Obtain special instructions before use.
 P264 Wash skin thoroughly after handling.
 P273 Avoid release to the environment.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
 P391 Collect spillage.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture

: Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	Flammable liquids, Category 4 Acute toxicity (Oral), Category 5 Skin irritation, Category 2 Eye irritation, Category 2A Reproductive toxicity, Category 1B Specific target organ toxicity - single exposure, Category 3	≥ 50 -< 70
Buparvaquone	88426-33-9	Skin irritation, Category 3 Eye irritation, Category 2B Short-term (acute) aquatic hazard, Category 1 Long-term (chronic) aquatic hazard, Category 1	≥ 5 -< 10

SECTION 4. FIRST AID MEASURES

General advice

:

In the case of accident or if you feel unwell, seek medical

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

		advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO _x)
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
---	---	--

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Avoid breathing mist or vapors.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitized individuals should consult their physician regarding working with respiratory irritants or sensitizers.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.

Buparvaquone Formulation

Version 4.1 Revision Date: 10.10.2020 SDS Number: 2091186-00007 Date of last issue: 23.03.2020
 Date of first issue: 17.10.2017

Materials to avoid : Keep tightly closed.
 Keep in a cool, well-ventilated place.
 Store in accordance with the particular national regulations.
 : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Buparvaquone	88426-33-9	TWA	20 µg/m ³ (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm ²	Internal

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapor type
 Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: liquid
Color	: clear, red
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: 1 (20 °C)
Density	: No data available
Solubility(ies) Water solubility	: No data available

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle size	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
---------------------	---	--

Components:**N-Methyl-2-pyrrolidone:**

Acute oral toxicity	:	LD50 (Rat): 4.150 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5,1 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403
Acute dermal toxicity	:	LD50 (Rat): > 5.000 mg/kg

Buparvaquone:

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

Acute oral toxicity : LD50 (Rat): > 8.000 mg/kg
LD50 (Mouse): > 50 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50: 2,5 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Causes skin irritation.

Components:**N-Methyl-2-pyrrolidone:**

Result : Skin irritation

Buparvaquone:

Species : Mouse
Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

Buparvaquone:

Result : Mild eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

Components:**N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
		Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative
		Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Method: OECD Test Guideline 474 Result: negative
		Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Hamster Application Route: Ingestion Method: OECD Test Guideline 475 Result: negative

Carcinogenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative
Species	:	Rat
Application Route	:	inhalation (vapor)
Exposure time	:	2 Years
Result	:	negative

Reproductive toxicity

May damage the unborn child.

Components:**N-Methyl-2-pyrrolidone:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion
----------------------	---	---

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

Method: OECD Test Guideline 416

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapor)
Result: positive

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Result: positive

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

May cause respiratory irritation.

Components:**N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****N-Methyl-2-pyrrolidone:**

Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408

Species : Rat
NOAEL : 0,5 mg/l
LOAEL : 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 96 Days
Method : OECD Test Guideline 413

Species : Rabbit
NOAEL : 826 mg/kg
LOAEL : 1.653 mg/kg

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

Application Route : Skin contact
Exposure time : 20 Days

Buparvaquone:

Species : Cat
NOAEL : 10 mg/kg
Application Route : Intramuscular
Exposure time : 5 d
Remarks : No significant adverse effects were reported

NOAEL : 5 mg/kg
Application Route : Intravenous
Exposure time : 4 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 6 d
Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:

Skin contact : Symptoms: Skin irritation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1.000 mg/l
Exposure time: 24 h
Method: DIN 38412

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600,5 mg/l
Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92,6 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12,5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

Toxicity to microorganisms : EC50: > 600 mg/l
Exposure time: 30 min
Method: ISO 8192

Buparvaquone:

Toxicity to fish : LC50 (Brachydanio rerio (zebrafish)): 0,484 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,013 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

M-Factor (Acute aquatic toxicity) : 10

M-Factor (Chronic aquatic toxicity) : 10

Persistence and degradability**Components:****N-Methyl-2-pyrrolidone:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Bioaccumulative potential**Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0,46
Method: OECD Test Guideline 107

Buparvaquone:

Partition coefficient: n-octanol/water : log Pow: 6,5

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: 9

IATA-DGR

UN/ID No.	: UN 3082
Proper shipping name	: Environmentally hazardous substance, liquid, n.o.s. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 964
Packing instruction (passenger aircraft)	: 964
Environmentally hazardous	: yes

IMDG-Code

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: 9
Hazard Identification Number	: 90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

International Regulations**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION**Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	10.10.2020	2091186-00007	Date of first issue: 17.10.2017

ment; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8